

Applicants: Eric Rose et al.
U.S. Serial No.: 09/053,872
Filed: April 1, 1998
Page 4

*b3
and 12*

patient may be a human being. The patient may also be subjected to extracorporeal life support. The patient may be a cardiogenic shock patient. The patient may be undergoing hemodialysis, continuous arterio-venous hemofiltration (CAVH), continuous veno-venous hemofiltration (CVVH), extracorporeal circulatory membrane oxygenation (ECMO), brain surgery, vascular surgery, abdominal surgery, orthopaedic surgery, hip replacement surgery, transplant surgery, or any surgery requiring cardio-pulmonary bypass. The subject may be any patient requiring a mechanical circulatory assistance or ventricle assist device (i.e. LVAD). The subject may be a patient requiring new devices as described in Wickelgren, 1996 such as implantable defibrillators. The subject may also be a patient suffering with symptoms of systemic lupus erythematosus or TTP (thrombotic thrombocytopenic purpura). The subject may also be a patient requiring plasmapharesis.--

In the claims:

Please amend claims 42 and 46 under the provisions of 37 C.F.R. §1.121(c) as follows: A marked up version of amended claims 42 and 46 wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit B.

--38.(Amended) A pharmaceutical composition which comprises an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier; wherein the

B4